Biomarkers of Oxidative Stress in Major Depressive Disorder

Rania A. Hamed; Heba A.  Elmalt; Abeer A.   Salama; Sarah Y.  Abozaid; Amani S.  Ahmed

doi:10.3889/oamjms.2020.4144

Authors

Rania A. Hamed Department of Psychiatry, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
Heba A. Elmalt Department of Medical Biochemistry, National Research Centre, Cairo, Egypt
Abeer A. Salama Department of Pharmacology, National Research Centre, Cairo, Egypt
Sarah Y. Abozaid Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
Amani S. Ahmed Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

DOI:

https://doi.org/10.3889/oamjms.2020.4144

Keywords:

Malondialdehyde, Nuclear factor erythroid 2-related factor 2, Superoxide dismutase, Major depressive disorder, Severity

Abstract

BACKGROUND: Many data support that oxidative stress and inflammation represent a pathway to pathology in a number of depressed patients. Therefore, investigating this pathway presents an area for developing potential therapeutic strategies for depression.

AIM: This study compares the serum level of malondialdehyde (MDA), superoxide dismutase (SOD), and nuclear factor erythroid 2-related factor 2 (Nrf2) in depressed and non-depressed subjects and correlate between their levels with severity of disorder, socio-demographic characteristics, previous hospitalization, and number of episodes.

METHODS: A total of 60 patients diagnosed with major depressive disorder (MDD) from the Psychiatric Outpatient Clinic in Al-Zahra University Hospital, Cairo, Egypt, during the period from July 1, 2018, to December 31, 2018. A cross-matched control group of 60 subjects was selected from employers working in the hospital, complete psychiatric history, Hamilton Depression rating scale was done and serum levels of MDA, Nrf2, and SOD were estimated.

RESULTS: No statistical difference between patient and control group was observed regarding age, sex, education, and marital status. The number of patients with mild depression was 28 (46.7%), moderate depression 18 (30%), and severe depression 14 (23.3%). The mean duration of illness in years was 6.13, and mean number of episodes was 3.66. MDA level was significantly elevated in the patient group than the control one. Meanwhile, SOD and Nrf2 were significantly lower in the patient group than the control. There was significant relationship between duration of illness and number of episodes and MDA, Nrf2, and SOD levels.

CONCLUSION: Our results indicate that oxidative stress can attribute to the occurrence of MDD.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mogi T, Toda H, Yoshino A. Clinical characteristics of patients with diagnostic uncertainty of major depressive disorder. Asian J Psychiatry 2017;30:159-62. https://doi.org/10.1016/j. ajp.2017.10.001 PMid:29055250

Stapelberg NJ, Pratt R, Neumann DL, Shum DH, Brandis S, Muthukkumarasamy V, et al. From feedback loop transitions to biomarkers in the psycho-immune-neuroendocrine network: Detecting the critical transition from health to major depression. Neurosci Biobehav Rev 2018;90:1-5. https://doi.org/10.1016/j. neubiorev.2018.03.005

World Health Organization. “Depression: Let’s Talk” Says WHO, as Depression Tops List of Causes of Ill Health. Geneva: World Health Organization; 2017. https://www.who.int/news-room/detail/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health. [Last accessed on 2017 Mar 30]. https://doi.org/10.7748/mhp.11.2.4.s2

World Health Organization. Preventing Suicide: A Global Imperative. Geneva: World Health Organization; 2014. Available from: https://www.who.int/mental_health/suicide-prevention/world_report_2014/en. https://doi.org/10.1037/ e400972004-001

Miller A. Five Things to know about Inflammation and Depression. Vol. 35. Psychiatric Times; 2018.

Kohler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: Systematic review and meta-analysis. Mol Neurobiol. 2018;55(5):4195-206. https://doi.org/10.1007/ s12035-017-0632-1 PMid:28612257

Semba RD, Ferrucci L, Sun K, Walston J, Varadhan R, Guralnik JM, et al. Oxidative stress is associated with greater mortality in older women living in the community. J Am Geriatr Soc 2007;55(9):1421-5. https://doi. org/10.1111/j.1532-5415.2007.01308.x PMid:17767685

Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(3):676-92. https://doi.org/10.1016/j. pnpbp.2010.05.004 PMid:20471444

Gupte AA, Lyon CJ, Hsueh WA. Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. Curr Diab Rep 2013;13(3):362-71. https://doi. org/10.1007/s11892-013-0372-1

Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Investig 2003;112(12):1821-30. https://doi.org/10.1172/jci200319451 PMid:14679177

Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 2016;7(1):1-4. https://doi.org/10.1038/ncomms11624 PMid:27211851

Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis 2017;1863(2):585-97. https://doi.org/10.1016/j. bbadis.2016.11.005 PMid:27825853

Kim JE, You DJ, Lee C, Ahn C, Seong JY, Hwang JI. Suppression of NF-κB signaling by KEAP1 regulation of IKKβ activity through autophagic degradation and inhibition of phosphorylation. Cell Signal 2010;22(11):1645-54. https://doi.org/10.1016/j. cellsig.2010.06.004 PMid:20600852

Harrison C. BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov 2012;11(2):96. https://doi. org/10.1038/nrd3656 PMid:22262035

Joshi G, A Johnson J. The Nrf2-ARE pathway: A valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 2012;7(3):218-29. https://doi.org/10.2174/157488912803252023 PMid:22742419

Martín-de-Saavedra MD, Budni J, Cunha MP, Gómez- Rangel V, Lorrio S, Del Barrio L, et al. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 2013;38(10):2010-22. https://doi. org/10.1016/j.psyneuen.2013.03.020 PMid:23623252

Mendez-David I, Tritschler L, El Ali Z, Damiens MH, Pallardy M, David DJ, et al. Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. Neurosci Lett 2015;597:121-6. https://doi.org/10.1016/j.neulet.2015.04.036 PMid:25916883

Martín-Hernández D, Caso JR, Meana JJ, Callado LF, Madrigal JL, García-Bueno B, et al. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: Effect of antidepressants. J Neuroinflammation 2018;15(1):251. https://doi.org/10.1186/ s12974-018-1294-2 PMid:30180869

Perry JJ, Shin DS, Getzoff ED, Tainer JA. The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta 2010;1804(2):245-62. https://doi.org/10.1016/j. bbapap.2009.11.004 PMid:19914407

Hamilton M. Standardised assessment and recording of depressive symptoms. Psychiatr Neurol Neurochir 1969;72(2):201-5. PMid:5792061

Fateem L. Arabic Manual of Hamilton Depression Scale. Cairo, Egypt: The Anglo-Egyptian Bookshop; 1994.

Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247(10):3170-5. PMid:4623845

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95(2):351-8. https://doi. org/10.1016/0003-2697(79)90738-3 PMid:36810

Whittemore ER, Loo DT, Watt JA, Cotmans CW. A detailed analysis of hydrogen peroxide-induced cell death in primary neuronal culture. Neuroscience 1995;67(4):921-32. https://doi. org/10.1016/0306-4522(95)00108-u PMid:7675214

Maes M. Major depression and activation of the inflammatory response system. In: Cytokines, Stress, and Depression. Boston, MA: Springer; 1999. p. 25-46.

Efe H, Değer O, Kirci D, Karahan SC, Örem A, Calapoğlu M. Decreased neutrophil antioxidative enzyme activities and increased lipid peroxidation in hyperlipoproteinemic human subjects. Clin Chim Acta 1999;279(1-2):155-65. https://doi. org/10.1016/s0009-8981(98)00178-8

Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O. Antioxidative enzyme activities and lipid peroxidation in major depression: Alterations by antidepressant treatments. J Affect Disord 2001;64(1):43-51. https://doi.org/10.1016/ s0165-0327(00)00199-3 PMid:11292519

Bajpai A, Verma AK, Srivastava M, Srivastava R. Oxidative stress and major depression. J Clin Diagn Res 2014;8(12):CC04-7. PMid:25653939

Camkurt MA, Fındıklı E, İzci F, Kurutaş EB, Tuman TC. Evaluation of malondialdehyde, superoxide dismutase and catalase activity and their diagnostic value in drug naïve, first episode, non-smoker major depression patients and healthy controls. Psychiatr Res 2016;238:81-85. https://doi. org/10.1016/j.psychres.2016.01.075

Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, Lanctôt KL. A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatr Dis Treat 2015;11:2479. https://doi.org/10.2147/ndt.s89922 PMid:26491326

Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 2015;18(4):pyu077. https://doi. org/10.1093/ijnp/pyu077 PMid:25628381

Rangaswamy R, Swathi K. Study of biochemical markers of oxidative and nitrosative stress pathways in major depression. J Evol Med Dent Sci 2014;42(3):10448-53. https://doi. org/10.14260/jemds/2014/3360

Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(5):1284-90. https://doi.org/10.1016/j.pnpbp.2011.03.021 PMid:21515329

Bal N, Acar ST, Yazici A, Yazici K, Tamer L. Altered levels of malondialdehyde and vitamin E in major depressive disorder and generalized anxiety disorder. Dusunen Adam 2012;25(3):206. https://doi.org/10.5350/dajpn2012250302

Rawdin BJ, Mellon SH, Dhabhar FS, Epel ES, Puterman E, Su Y, et al. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 2013;31:143- 52. https://doi.org/10.1016/j.bbi.2012.11.011 PMid:23201587

Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: Short-term antidepressant treatment does not alter oxidative antioxidative systems. Hum Psychopharmacol 2007;22(2):67- 73. https://doi.org/10.1002/hup.829 PMid:17299810

Stefanescu C, Ciobica A. The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disord. 2012;143(1-3):34-8. https://doi.org/10.1016/j.jad.2012.05.022 PMid:22840610

Maes M, Vandoolaeghe E, Van Hunsel F, Bril T, Demedts P, Wauters A, et al. Immune disturbances in treatment-resistant depression: Modulation by antidepressive treatments. Hum Psychopharmacol 1997;12(2):153-62. https://doi.org/10.1002/ (sici)1099-1077(199703/04)12:2<153::aid-hup852>3.0.co;2-n